Cancer Prevention and Research Institute of Texas logo
CPRIT Product Development Research

CPRIT PDR — Texas Therapeutics Company

Funds Texas oncology companies with revenue-sharing support as therapies move toward commercialization.

OpenCancer Prevention and Research Institute of TexasUnited StatesEligible in Texas

The CPRIT Texas Therapeutics Company RFA is one of four Product Development Research mechanisms administered by the Cancer Prevention and Research Institute of Texas, which allocates approximately $70 million per fiscal year to product development awards. The Therapeutics RFA funds Texas-based for-profit companies developing novel cancer therapeutics at or near the IND-enabling or Phase 1 stage. E

Cancer therapeutics development by Texas-based for-profit companies at or near IND filing or Phase 1, covering preclinical proof of concept through early clinical trials.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Rolling
Next deadlineiThe next date applications are due. Rolling means you can apply any time.Rolling
Decision timeiTypical time from the deadline to the funder's decision.4 weeks
Project durationiHow long the funded work is expected to run.36 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Royalty-back
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.50%
Funding pooliThe total budget available across all awards in this round.

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see the timeline

Last verified: 22 Jul 2026Source: cprit.texas.gov